Potent anti-HIV activity of scytovirin domain 1 peptide

Peptides

Volumn 27, Issue 7, 2006, Pages 1668-1675

  Xiong, Changyun ^a   O'Keefe, Barry R ^a   Byrd, R Andrew ^a   McMahon, James B ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Anti viral; HIV; Microbicide; Scytovirin; SD1; SD2

Indexed keywords

CYSTEINE; DISULFIDE; DNA; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; POLYPEPTIDE ANTIBIOTIC AGENT; SCYTOVIRIN; SCYTOVIRIN DOMAIN 1 PEPTIDE; SERINE; THIOREDOXIN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; AQUEOUS SOLUTION; ARTICLE; BACTERIUM CULTURE; BINDING AFFINITY; CONTROLLED STUDY; CYANOBACTERIUM; DELETION MUTANT; DISULFIDE BOND; DRUG ISOLATION; DRUG POTENCY; ESCHERICHIA COLI; FUSION GENE; GENE CONSTRUCT; GENE EXPRESSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RECOMBINANT GENE; SCYTONEMA VARIUM; SEQUENCE HOMOLOGY; SURFACE PROPERTY; VIRUS PURIFICATION; WHOLE CELL;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; BACTERIAL PROTEINS; CARRIER PROTEINS; DISULFIDES; DNA; ESCHERICHIA COLI; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; LECTINS; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; SEQUENCE ANALYSIS, DNA;

SCYTONEMA;

EID: 33745034288     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2006.03.018     Document Type: Article

References (21)

1. http://sx102a.niddk.nih.gov/peptide
2. Adams E.W., Ratner D.M., Bokesch H.R., McMahon J.B., O'Keefe B.R., and Seeberger P.H. Oligosaccharide and glycoprotein microarrays as tools in HIV glycobiology; glycan-dependent gp120/protein interactions. Chem Biol 11 6 (2004) 875-881
3. Bokesch H.R., O'Keefe B.R., McKee T.C., Pannell L.K., Patterson G.M., Gardella R.S., et al. A potent novel anti-HIV protein from the cultured cyanobacterium Scytonema varium. Biochemistry 42 9 (2003) 2578-2584
4. Botos I., and Wlodawer A. Proteins that bind high-mannose sugars of the HIV envelope. Prog Biophys Mol Biol 88 2 (2005) 233-282
5. Boyd M.R., Gustafson K.R., McMahon J.B., Shoemaker R.H., O'Keefe B.R., Mori T., et al. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential application to microbicide development. Antimicrob Agents Chemother 41 7 (1997) 1521-1530
6. Chen R.Y., Kilby J.M., Saag M.S., and Enfuvirtide. Expert Opin Investig Drugs 11 (2002) 1837-1843
7. Cole A.M. Antimicrobial peptide microbicides targeting HIV. Protein Pept Lett 12 1 (2005) 41-47
8. Gordon Y.J., G E.G., and McDermott A.M. A review of antimicrobial peptides and their therapeutic potential as anti-infective drugs. Curr Eye Res 30 7 (2005) 505-515
9. Gulakowski R.J., McMahon J.B., Staley P.G., Moran R.A., and Boyd M.R. A semiautomated multiparameter assay for anti-HIV drug screening. J Virol Methods 33 (1991) 87-100
10. Han Z., Xiong C., Mori T., and Boyd M.R. Discovery of a stable dimeric mutant of cyanovirin-N (CV-N) from a T7 phage-displayed CV-N mutant library. Biochem Biophys Res Commun 292 4 (2002) 1036-1043
11. Jacobson J.M., Israel R.J., Lowy I., Ostrow N.A., Vassilatos L.S., Barish M., et al. Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother 48 (2004) 423-429
12. Kilby J.M., Hopkins S., Venetta T.M., DiMassimo B., Cloud G.A., Lee J.Y., et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 4 11 (1998) 1302-1307
13. Lalezari J.P., Eron J.J., Carlson M., Cohen C., DeJesus E., Arduino R.C., et al. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS 17 5 (2003) 691-698
14. Lalezari J.P., Henry K., O'Hearn M., Montaner J.S., Piliero P.J., Trottier B., et al., TORO 1 Study Group. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 348 22 (2003) 2175-2185
15. Martin L., Stricher F., Missé D., Sironi F., Pugnière M., Barthe P., et al. Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. Nat Biotechnol 21 (2003) 71-76
16. Mori T., Shoemaker R.H., Gulakowski R.J., Krepps B.L., McMahon J.B., Gustafson K.R., et al. Analysis of sequence requirements for biological activity of cyanovirin-N, a potent HIV (human immunodeficiency virus)-inactivating protein. Biochem Biophys Res Commun 238 1 (1997) 218-222
17. O'Keefe B.R. Biologically active proteins from natural product extracts. J Nat Prod 64 10 (2001) 1373-1381
18. O'Keefe B.R., Shenoy S.R., Xie D., Zhang W., Muschik J.M., Currens M.J., et al. Analysis of the interaction between the HIV-inactivating protein cyanovirin-N and soluble forms of the envelope glycoproteins gp120 and gp41. Mol Pharmacol 58 (2000) 982-992
19. Ryser H.J., and Fluckiger R. Progress in targeting HIV-1 entry. Drug Discov Today 10 16 (2005) 1085-1094
20. Tamamura H., Otaka A., and Fujii N. Development of anti-HIV agents targeting dynamic supramolecular mechanism: entry and fusion inhibitors based on CXCR4/CCR5 antagonists and gp41-C34-remodeling peptides. Curr HIV Res 3 4 (2005) 289-301
21. Xiong C., O'keefe B.R., Botos I., Wlodawer A., and McMahon J.B. Overexpression and purification of scytovirin, a potent, novel anti-HIV protein from the cultured cyanobacterium Scytonema varium. Protein Expr Purif 46 2 (2006) 233-239